, Volume 20, Issue 8, pp 1451-1458
Date: 17 Jun 2009

Dietary vitamin C, E, and carotenoid intake and risk of renal cell carcinoma

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Object

The study examines the association between dietary intake of vitamin C, E, and carotenoids and the risk of renal cell carcinoma (RCC).

Methods

Between 1994 and 1997 in 8 Canadian provinces, mailed questionnaires were completed by 1,138 incident, histologically confirmed cases of RCC and 5,039 population controls, including information on socio-economic status, lifestyle habits and diet. A 69-item food frequency questionnaire provided data on eating habits 2 years before data collection. Odds ratios (OR) and 95% confidence intervals (CI) were computed using unconditional logistic regression.

Results

Dietary intake of β-carotene and lutein/zeaxanthin was inversely associated with the risk of RCC. The ORs for the highest versus the lowest quartile were 0.74 (95% CI, 0.59–0.92) and 0.77 (95% CI, 0.62–0.95), respectively. The significant inverse association with β-carotene and lutein/zeaxanthin was more pronounced in women, and in overweight or obese subjects. The relation of lutein/zeaxanthin to RCC was stronger in ever smokers. No clear association was observed with vitamin C and E, β-cryptozanthin, and lycopene.

Conclusion

The findings provide evidence that a diet rich in β-carotene and lutein/zeaxanthin may play a role in RCC prevention.

The Canadian Cancer Registries Epidemiology Research Group comprises a principal investigator from each of the provincial cancer registries involved in the National Enhanced Cancer Surveillance System: Bertha Paulse, MSc, BN, Newfoundland Cancer Foundation; Ron Dewar, MA, Nova Scotia Cancer Registry; Dagny Dryer, MD, Prince Edward Island Cancer Registry; Nancy Kreiger, PhD, Cancer Care Ontario; Heather Whittaker, Manitoba Cancer Treatment and Research Foundation; Diane Robson, BA, Saskatchewan Cancer Foundation; Shirley Fincham, PhD, Alberta Cancer Board; and Nhu Le, PhD, British Columbia Cancer Agency.